NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVB and the CUSIP is 63937X202. A total of 36 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q4 2020. The put-call ratio across all filers is 1.16 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $17,812 | -18.6% | 68,507 | -34.2% | 0.00% | – |
| Q4 2022 | $21,871 | +143.0% | 104,149 | +205.4% | 0.00% | – |
| Q3 2022 | $9,000 | -79.5% | 34,100 | -44.7% | 0.00% | – |
| Q2 2022 | $44,000 | +18.9% | 61,617 | +32.9% | 0.00% | – |
| Q1 2022 | $37,000 | -65.1% | 46,362 | -55.9% | 0.00% | – |
| Q4 2021 | $106,000 | -35.8% | 105,062 | +11.3% | 0.00% | – |
| Q3 2021 | $165,000 | -33.5% | 94,437 | -30.6% | 0.00% | – |
| Q2 2021 | $248,000 | +11.2% | 136,143 | +22.9% | 0.00% | – |
| Q1 2021 | $223,000 | +38.5% | 110,814 | +48.2% | 0.00% | – |
| Q4 2020 | $161,000 | +28.8% | 74,795 | +61.9% | 0.00% | – |
| Q3 2020 | $125,000 | -29.0% | 46,192 | +3.6% | 0.00% | – |
| Q2 2020 | $176,000 | +738.1% | 44,598 | +58.6% | 0.00% | – |
| Q1 2020 | $21,000 | +5.0% | 28,127 | -2.7% | 0.00% | – |
| Q3 2019 | $20,000 | +81.8% | 28,915 | +72.4% | 0.00% | – |
| Q2 2019 | $11,000 | – | 16,769 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Allred Capital Management, LLC | 52,926 | $113,000 | 0.06% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 109,940 | $236,000 | 0.01% |
| PATHSTONE FAMILY OFFICE, LLC | 10,050 | $22,000 | 0.00% |
| Sowell Financial Services LLC | 11,190 | $24,000 | 0.00% |
| TWO SIGMA INVESTMENTS, LP | 101,949 | $219,000 | 0.00% |
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 32,822 | $71,000 | 0.00% |
| UBS Group AG | 816 | $2,000 | 0.00% |
| IFP Advisors, Inc | 50 | $0 | 0.00% |
| OSAIC HOLDINGS, INC. | 6 | $0 | 0.00% |
| Jacobi Capital Management LLC | 1,000 | $2,000 | 0.00% |